The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
The comprehensive development of new antineoplastic agents mandates a thorough evaluation of schedule-dependent cytotoxicity and toxicity. This report focuses on the topoisomerase I inhibitors as an example of a novel class of anticancer agents in exposure duration may be a critical factor in the achievement of an optimal therapeutic index. The mechanistic and pharmacologic determinants and rationale for using protracted exposure schedules in administering several topoisomerase I inhibitors are discussed. The review also discusses dihydropyrimidine dehydrogenase as a pharmacologic target, enabling administration of oral fluoropyrimidines.